January 05, 2024

REIMAGINE 4: A research study to see how much CagriSema lowers blood sugar and body weight compared to tirzepatide (Mounjaro) people with type 2 diabetes treated with metformin with or without an SGLT2 inhibitor

The University of Alabama at Birmingham, Department of Nutrition Sciences, is conducting a 75-week research study to evaluate the effectiveness of an investigational drug to treat type 2 diabetes. In this trial you will receive one of two possible once-weekly injectable medications: either semaglutide/cagrlintide (CagriSema) or tirzepatide (Mounjaro) along with diet and exercise counseling. To qualify, you must be 18 years old or older and have Type 2 Diabetes. Qualified participants will receive study drug, diabetes counseling, EKGs, eye exams, and physical exams. There is no charge for participation. Compensation for time and travel may also be available. For more information, and to see if you might be eligible to join, please contact (205)996-4015 or ccnrn@uab.edu.